Xinda Bio and Lilly cooperation in the next city, home-made PD-1 Daboshu will go to North America and Europe.

"Pharmaceutical Network Industry Dynamics" August 18, Xinda Bio and Lilly Pharmaceuticals announced that the cooperation between the two sides will be next city.
the innovative drug PD-1 monoclonal antibody immuno-oncology drug Dabershu (Syndili monoantigen injection) will be developed jointly by the two sides to North America, Europe and other regions, benefiting more cancer patients around the world.
, lung cancer is a very common malignant tumor, with morbidity and mortality among all malignant tumors.
lung cancer seriously endangers public health, according to statistics, China's annual incidence of lung cancer more than 730,000 people, lung cancer death toll of more than 610,000, and the overall five-year survival rate of only 16.1%.
According to data released by the National Cancer Center in 2019, non-small cell lung cancer patients account for 80 to 85 percent of the total number of lung cancer cases, and about 70 percent of patients are diagnosed with local late-stage or metastasis tumors that are not suitable for root surgery.
, a domestic PD-1 drug, has been included in the medical insurance list, compared with the price of similar imported drugs, is conducive to greatly reducing the burden on patients.
Xinda Bio recently issued a notice on the Hong Kong Stock Exchange, disclosing the first half of 2020 sales data of Daboshu (Xindili single anti-injection).
, sales of the product in the first quarter were about 400 million yuan, and sales in the second quarter were about 500 million yuan.
first half of this year, Dabershu's sales were close to 1 billion yuan for the whole of 2019, which is comparable to O-drug sales in China in 2019.
At the 21st World Lung Cancer Congress held on August 8 this year, clinical data from Phase III of the first-line treatment of non-small cell lung cancer by Dabershu (Syndili mono-injection) showed that the combined chemotherapy of Dabshu (Syndili mono-injection) significantly delayed the progression of disease in patients with advanced non-squamous non-small cell lung cancer.
in April, the National Drug Administration (NMPA) formally accepted Dabshu's application for a new adaptation for the first-line treatment of non-squamous non-small cell lung cancer and is expected to be approved by the end of this year or early next year.
It is worth mentioning that Cinda Bio also recently announced that another clinical study on the first-line treatment of late-stage or metastasis squamous non-small cell lung cancer has also reached the end of the main study, and on August 12, the State Drug Administration officially accepted Dabshu's application for new adaptation to the first-line treatment of squamous non-small cell lung cancer.
new adaptations are approved, they are expected to lead to more treatment options for patients.
it is understood that between 2020 and early 2021, Cinda Bio will submit four applications for the listing of daboshu's new drug (NDA), covering lung cancer, liver cancer and other cancers with a large base of patients.
At the same time, Xinta Bio is conducting clinical research on Syndicate monoantigen injections worldwide, and more than 20 clinical studies (more than 10 of which are registered clinical trials) are under way to assess the anti-tumor effects of Syndicate in a variety of solid and blood tumors, which will benefit more tumor patients in the future.
, the domestic PD-1 market has been approved for listing 8 PD-1/PD-L1 drugs, including 6 PD-1 monoantigens and 2 PD-L1 monoantigens.
, 4 domestic PD-1 production enterprises have been listed, and 4 enterprises are about to be listed, and many others are in clinical phase II trials.
, according to recently disclosed data, in the first half of this year, Xinda Bio, Junshi Bio, Baiji Shenzhou, Hengrui Pharmaceutical four enterprises PD-1 products generated a total market share of more than 2.2 billion yuan.
.